MEKINIST
Total Payments
$70.4M
Transactions
32,816
Doctors
8,438
Companies
4
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $5.4M | 4,976 | 3,043 |
| 2023 | $4.9M | 55 | 24 |
| 2022 | $5.5M | 5,580 | 2,820 |
| 2021 | $4.1M | 5,168 | 2,257 |
| 2020 | $4.6M | 1,902 | 1,126 |
| 2019 | $8.4M | 5,419 | 2,352 |
| 2018 | $18.9M | 5,090 | 2,271 |
| 2017 | $18.6M | 4,626 | 2,293 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $67.5M | 395 | 95.8% |
| Consulting Fee | $1.1M | 350 | 1.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $738,780 | 229 | 1.0% |
| Food and Beverage | $584,063 | 31,040 | 0.8% |
| Space rental or facility fees (teaching hospital only) | $196,225 | 137 | 0.3% |
| Travel and Lodging | $188,285 | 583 | 0.3% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $89,141 | 24 | 0.1% |
| Education | $348.00 | 58 | 0.0% |
Payments by Type
Research
$67.5M
395 transactions
General
$2.9M
32,421 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PHASE I AND OR II STUDY OF SAFETY AND EFFICACY OF RIBOCICLIB LEE011 IN COMBINATION WITH TRAMETINIB TMT212 IN PATIENTS WITH METASTATIC OR ADVANCED SOLID TUMORS | Novartis Pharmaceuticals Corporation | $12.3M | 0 |
| AN OPEN LABEL DOSE ESCALATION PHASE I AND OR II STUDY TO INVESTIGATE THE SAFETY PHARMACOKINETICS PHARMACODYNAMICS AND CLINICAL ACTIVITY OF THE MEK INHIBITOR TRAMETINIB IN CHILDREN AND ADOLESCENTS SUBJECTS WITH CANCER OR PLEXIFORM NEUROFIBROMAS AND TRAMETI | Novartis Pharmaceuticals Corporation | $9.3M | 1 |
| A Phase I Trial Evaluating the Combination of Trametinib and Everolimus in Pediatric and Young Adult Patients with Recurrent Low Grade Gliomas | Novartis Pharmaceuticals Corporation | $6.6M | 0 |
| A PHASE I TRIAL EVALUATING THE COMBINATION OF TRAMETINIB AND EVEROLIMUS IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH RECURRENT LOW GRADE GLIOMAS | Novartis Pharmaceuticals Corporation | $4.7M | 0 |
| ADVL1521 A PHASE 2 STUDY OF THE MEK INHIBITOR TRAMETINIB IN CHILDREN WITH RELAPSED OR REFRACTORY JUVENILE MYELOMONOCYTIC LEUKEMIA | NOVARTIS PHARMACEUTICALS CORPORATION | $2.3M | 0 |
| ADVL1521 A PHASE 2 STUDY OF THE MEK INHIBITOR TRAMETINIB IN CHILDREN WITH RELAPSED OR REFRACTORY JUVENILE MYELOMONOCYTIC LEUKEMIA | Novartis Pharmaceuticals Corporation | $2.3M | 0 |
| A PHASE I OPEN LABEL STUDY TO DETERMINE THE EFFECT OF REPEAT DOSING OF TRAMETINIB ON THE PHARMACOKINETICS AND SAFETY OF A COMBINED ORAL CONTRACEPTIVE NORETHINDRONE PLUS ETHINYL ESTRADIOL AND TO CHARACTERIZE THE PHARMACOKINETICS OF TRAMETINIBS METABOLITE M5 IN FEMALE SUBJECTS WITH SOLID TUMORS | Novartis Pharmaceuticals Corporation | $2.1M | 0 |
| MOLECULAR PROFILING BASED ASSIGNMENT OF CANCER THERAPY FOR PATIENTS WITH ADVANCED SOLID TUMORS | Novartis Pharmaceuticals Corporation | $2.0M | 0 |
| A PHASE II ENRICHMENT STUDY OF PANITUMUMAB IN COMBINATION WITH TRAMETINIB IN CETUXIMAB REFRACTORY STAGE IV COLORECTAL CANCER PATIENTS | Novartis Pharmaceuticals Corporation | $1.9M | 0 |
| PHASE II STUDY OF DURVALUMAB ANTI PD L1 AND TRAMETINIB MEKI IN MSS METASTATIC COLON CANCER | Novartis Pharmaceuticals Corporation | $1.9M | 0 |
| A PHASE I CLINICAL TRIAL OF TRAMETINIB IN COMBINATION WITH TAS 102 IN PATIENTS WITH CHEMOTHERAPY RESISTANT METASTATIC COLORECTAL CANCER | Novartis Pharmaceuticals Corporation | $1.8M | 0 |
| PHASE I CLINICAL TRIAL OF MEK INHIBITOR TRAMETINIB IN THE TREATMENT OF COMPLICATED EXTRACRANIAL ARTERIAL VENOUS MALFORMATION | Novartis Pharmaceuticals Corporation | $1.7M | 0 |
| A RANDOMIZED SINGLE CENTER OPEN LABEL STUDY TO INVESTIGATE THE RELATIVE BIOAVAILABILITY OF 24 MONTHS SHELF LIFE DMSO TESTING IN HEALTHY SUBJECTS | Novartis Pharmaceuticals Corporation | $1.5M | 0 |
| PILOT STUDY OF PACLITAXEL AND TRAMETINIB FOR THE TREATMENT OF ANAPLASTIC THYROID CANCER | Novartis Pharmaceuticals Corporation | $1.5M | 0 |
| A PHASE I II TRIAL OF TRAMETINIB AND ERLOTINIB IN PATIENTS WITH EGFR MUTANT LUNG ADENOCARCINOMAS AND ACQUIRED RESISTANCE TO ERLOTINIB | Novartis Pharmaceuticals Corporation | $1.5M | 0 |
| A phase 1 trial of combined MEK, STAT3 and PD-1 inhibition in metastatic pancreatic ductal adenocarcinoma | Novartis Pharmaceuticals Corporation | $1.4M | 0 |
| BATTLE IMMUNOTHERAPY A RANDOMIZED PHASE II TRIAL OF TRAMETINIB IN COMBINATION WITH MK 3475 ANTI PD1 ANTIBODY VERSUS MK 3475 ANTI PD1 ANTIBODY IN ADVANCED REFRACTORY TO FRONTLINE CHEMOTHERAPY NSCLC | Novartis Pharmaceuticals Corporation | $1.4M | 0 |
| Phase I Clinical Trial of MEK Inhibitor Trametinib in the Treatment of Complicated Extracranial Arterial Venous Malformation | Novartis Pharmaceuticals Corporation | $1.2M | 0 |
| TMT212 + HCQ IN PANCREATIC CANCER | Novartis Pharmaceuticals Corporation | $1.1M | 0 |
| GENERAL PROGRAM SUPPORT FOR TMT212X | Novartis Pharmaceuticals Corporation | $1.0M | 0 |
Top Doctors Receiving Payments for MEKINIST — Page 338
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Hematology & Oncology | Arroyo Grande, CA | $6.80 | 1 |
| , RN, ARNP | Adult Health | Chehalis, WA | $6.70 | 1 |
| , MD | Medical Oncology | Puyallup, WA | $6.70 | 1 |
| , CNP | Nurse Practitioner | Fort Smith, AR | $6.23 | 1 |
| , MD | Hematology & Oncology | Muncie, IN | $6.08 | 1 |
| , MD | Hematology & Oncology | Belleville, NJ | $5.90 | 2 |
| , M.D | Hematology & Oncology | Williamsville, NY | $4.62 | 1 |
| , M.D | Hematology & Oncology | Huntsville, AL | $4.60 | 1 |
| , MD | Hematology & Oncology | Seneca, SC | $3.76 | 1 |
| , MD | Hematology & Oncology | Howard Beach, NY | $3.48 | 1 |
| , M.D., PH.D | Dermatology | North Wales, PA | $2.79 | 1 |
| , DO | Internal Medicine | Flint, MI | $2.58 | 1 |
| , M.D | Hematology & Oncology | Flint, MI | $2.58 | 1 |
| , M.D | Hematology | Poughkeepsie, NY | $2.50 | 1 |
Ad
Manufacturing Companies
- Novartis Pharmaceuticals Corporation $67.4M
- NOVARTIS PHARMACEUTICALS CORPORATION $2.8M
- Deciphera Pharmaceuticals Inc. $170,470
- Novartis Pharma AG $20,629
Product Information
- Type Drug
- Total Payments $70.4M
- Total Doctors 8,438
- Transactions 32,816
About MEKINIST
MEKINIST is a drug associated with $70.4M in payments to 8,438 healthcare providers, recorded across 32,816 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2024. In 2024, $5.4M was paid across 4,976 transactions to 3,043 doctors.
The most common payment nature for MEKINIST is "Unspecified" ($67.5M, 95.8% of total).
MEKINIST is associated with 20 research studies, including "A PHASE I AND OR II STUDY OF SAFETY AND EFFICACY OF RIBOCICLIB LEE011 IN COMBINATION WITH TRAMETINIB TMT212 IN PATIENTS WITH METASTATIC OR ADVANCED SOLID TUMORS" ($12.3M).